[go: up one dir, main page]

DE60219917D1 - Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen - Google Patents

Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen

Info

Publication number
DE60219917D1
DE60219917D1 DE60219917T DE60219917T DE60219917D1 DE 60219917 D1 DE60219917 D1 DE 60219917D1 DE 60219917 T DE60219917 T DE 60219917T DE 60219917 T DE60219917 T DE 60219917T DE 60219917 D1 DE60219917 D1 DE 60219917D1
Authority
DE
Germany
Prior art keywords
alzheimer
treatment
inhibitors
tau aggregation
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60219917T
Other languages
English (en)
Other versions
DE60219917T2 (de
Inventor
Claude M Wischik
David Horsley
Janet E Rickard
Charles R Harrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of DE60219917D1 publication Critical patent/DE60219917D1/de
Application granted granted Critical
Publication of DE60219917T2 publication Critical patent/DE60219917T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60219917T 2001-07-16 2002-07-16 Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen Expired - Lifetime DE60219917T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0117326.9A GB0117326D0 (en) 2001-07-16 2001-07-16 Napthoquinone-type inhibitors of protein aggregation
GB0117326 2001-07-16
PCT/GB2002/003269 WO2003007933A1 (en) 2001-07-16 2002-07-16 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders

Publications (2)

Publication Number Publication Date
DE60219917D1 true DE60219917D1 (de) 2007-06-14
DE60219917T2 DE60219917T2 (de) 2008-01-17

Family

ID=9918593

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60219917T Expired - Lifetime DE60219917T2 (de) 2001-07-16 2002-07-16 Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen

Country Status (13)

Country Link
US (1) US7605179B2 (de)
EP (1) EP1408952B1 (de)
JP (1) JP5147157B2 (de)
CN (1) CN1313088C (de)
AT (1) ATE361067T1 (de)
AU (1) AU2002317354B2 (de)
CA (1) CA2451422C (de)
DE (1) DE60219917T2 (de)
ES (1) ES2287292T3 (de)
GB (1) GB0117326D0 (de)
HK (1) HK1063012A1 (de)
SG (1) SG148846A1 (de)
WO (1) WO2003007933A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2005000288A2 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders
WO2005053609A2 (en) * 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
WO2006007864A1 (en) * 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
FR2874923B1 (fr) * 2004-09-07 2006-10-27 Trophos Sa Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
JP4734602B2 (ja) 2004-12-21 2011-07-27 Ｄｏｗａエレクトロニクス株式会社 保存安定性に優れた窒化鉄系磁性粉末
JP4822312B2 (ja) * 2005-05-13 2011-11-24 学校法人慶應義塾 ナフトキノン誘導体化合物
KR100699945B1 (ko) * 2005-11-24 2007-03-26 (주) 디지탈바이오텍 나프토퀴논계 화합물을 함유하는 인지기능 장애의 예방 및 치료용 조성물
DK2013191T6 (en) 2006-03-29 2019-04-23 Wista Lab Ltd 3,7-Diamino-10H-phenothiazine salts and their use
CN101460157B (zh) 2006-03-29 2015-09-02 维斯塔实验室有限公司 蛋白聚集抑制剂
WO2008002465A2 (en) * 2006-06-23 2008-01-03 The Feinstein Institute For Medical Research INHIBITORS OF Aβ AND SYNUCLEIN AGGREGATION
RU2446793C2 (ru) * 2007-04-05 2012-04-10 Й-Оил Миллс, Инц. Транквилизатор и функциональный продукт питания
WO2009033151A1 (en) * 2007-09-07 2009-03-12 The Trustees Of Columbia University In The City Of New York Tau protein screening assay
EP2060256A1 (de) * 2007-11-16 2009-05-20 Gnosis S.p.A. Auf Menaquinolen basierende pharmazeutische und nutrazeutische Zusammensetzungen
GB0816269D0 (en) * 2008-09-05 2008-10-15 Univ Ramot Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease
EP2550361B1 (de) 2010-03-25 2017-02-08 The J. David Gladstone Institutes Zusammensetzungen und verfahren zur behandlung neurologischer störungen
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
BR112013002877A2 (pt) * 2010-08-06 2016-05-31 Edison Pharmaceuticals Inc tratamento de doenças mitocondriais com naftoquinonas
EP2670434B1 (de) 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Behandlung von tauopathien
SG192666A1 (en) 2011-02-11 2013-09-30 Wista Lab Ltd Phenothiazine diaminium salts and their use
CA2831331C (en) 2011-04-21 2019-10-15 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
WO2012170773A1 (en) * 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
US20140249180A1 (en) 2011-10-03 2014-09-04 National Center For Geriatrics And Gerontology Tau aggregation inhibitor
US9938560B2 (en) 2012-02-05 2018-04-10 Biodesy, Inc. Methods for identifying modulators of Ras using nonlinear techniques
WO2014028777A2 (en) 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
JP6393684B2 (ja) 2012-09-07 2018-09-19 バイオエレクトロン テクノロジー コーポレイション 個体のレドックス状態の調節において使用するためのキノン誘導体
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
CN116063483A (zh) 2012-11-02 2023-05-05 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
WO2014162737A1 (ja) 2013-04-02 2014-10-09 学校法人同志社 タウ凝集阻害剤
BR112015030356A2 (pt) 2013-06-10 2017-12-05 Ipierian Inc métodos de tratamento de uma taupatia
GB2538216A (en) * 2013-06-13 2016-11-16 Biodesy Inc Method of screening candidate biochemical entities targeting a target biochemical entity
US20150166476A1 (en) * 2013-12-17 2015-06-18 Yi-Cheng Chen Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
EP3773530A4 (de) 2018-03-30 2022-03-02 Kaydence Pharma AS Schnelle verbesserung von gefässerkrankungen durch verabreichung von vitamin k
EP3946605A1 (de) 2019-04-05 2022-02-09 Tauc3 Biologics Limited Anti-tauc3-antikörper und verwendungen davon
CN110025624B (zh) * 2019-05-29 2021-04-02 济宁医学院附属医院 萘醌苷类化合物在老年痴呆中的应用及其药物制备
CN112778092B (zh) * 2020-12-31 2023-03-24 玉溪健坤生物药业有限公司 一种还原型维生素k2的制备方法及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175449A (ja) * 1983-03-26 1984-10-04 Kyushu Kogyo Daigaku シコニンの製造法
JPS61143334A (ja) * 1984-12-18 1986-07-01 Mitsui Petrochem Ind Ltd ５，８−ジヒドロキシ−１，４−ナフトキノン誘導体
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US5763479A (en) * 1991-02-04 1998-06-09 Ks Biomedix Ltd. Naphthoquinone derivatives for the treatment of chronic inflammation
JPH07507044A (ja) 1991-12-06 1995-08-03 マックス−プランク−ゲゼルシャフト　ツール　フェルデルング　デル　ヴィッセンシャフテン　エー．ヴェー． アルツハイマー病の診断および治療用の新規な手段
WO1996004915A1 (en) 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
JPH08193026A (ja) * 1995-01-12 1996-07-30 Teijin Ltd アミロイドβ蛋白凝集・沈着阻害剤
DE19504003A1 (de) * 1995-02-08 1996-08-14 Martin Dr Kohlmeier Verwendungen eines Vitamins der K-Gruppe
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) * 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
KR0180791B1 (ko) * 1995-07-24 1999-05-15 김용옥 6-치환-5,8-디옥시-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도
JP3809014B2 (ja) * 1998-05-22 2006-08-16 花王株式会社 養毛・育毛剤
US20020040011A1 (en) 2000-06-01 2002-04-04 Brown Dennis M. Naphthoquinone compositions and uses thereof
US20020016372A1 (en) 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
EP3564223A1 (de) 2004-09-23 2019-11-06 WisTa Laboratories Ltd. Verfahren zur chemischen synthese und aufreinigung von diaminophenothiaziniumverbindungen mit methylthioniniumchlorid (mtc)

Also Published As

Publication number Publication date
AU2002317354B2 (en) 2007-07-19
GB0117326D0 (en) 2001-09-05
US7605179B2 (en) 2009-10-20
CN1553800A (zh) 2004-12-08
ATE361067T1 (de) 2007-05-15
SG148846A1 (en) 2009-01-29
ES2287292T3 (es) 2007-12-16
CA2451422C (en) 2010-10-19
HK1063012A1 (en) 2004-12-10
CA2451422A1 (en) 2003-01-30
CN1313088C (zh) 2007-05-02
JP2004534854A (ja) 2004-11-18
JP5147157B2 (ja) 2013-02-20
DE60219917T2 (de) 2008-01-17
US20050107472A1 (en) 2005-05-19
EP1408952B1 (de) 2007-05-02
WO2003007933A1 (en) 2003-01-30
EP1408952A1 (de) 2004-04-21

Similar Documents

Publication Publication Date Title
DE60219917D1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
DE122012000007I1 (de) Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung.
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
NO20034056D0 (no) Proliferative sykdommer
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
NO961326D0 (no) Inhibitorer av
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE60237635D1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE553114T1 (de) Verbindungen zur verminderung der aggregation von amyloid-beta-peptid
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
BR0314541A (pt) Tratamento de demência e doença de parkinson
DE602004024992D1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten
DE602004014115D1 (de) Neue amidderivate von 2,2,3,3-tetramethylcyclopropancarbonsäure
MY135225A (en) Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition